Cipla | |
Formerly | Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) |
Company type | Public |
BSE: 500087 NSE: CIPLA NSE NIFTY 50 constituent | |
ISIN | INE059A01026 |
Industry | Pharmaceuticals |
Founded | 1935 |
Founder | Khwaja Abdul Hamied |
Headquarters | Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people |
|
Products | |
Revenue | ₹25,455 crore (US$3.0 billion) (FY24)[1] |
₹6,233 crore (US$750 million) (FY24)[1] | |
₹4,106 crore (US$490 million) (FY24)[1] | |
Total assets | ₹32,511 crore (US$3.9 billion) (FY24)[1] |
Total equity | ₹26,706 crore (US$3.2 billion) (FY24)[1] |
Number of employees | 22,036[2] |
Subsidiaries | Invagen Pharmaceuticals |
Website | www.cipla.com |
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions.[3] Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.[4][5]